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Abstract For the ﬁrst time the immunonutritional role of
pyruvate on neutrophils (PMN), free a-keto and amino acid
proﬁles, important reactive oxygen species (ROS) pro-
duced [superoxide anion (O2
-), hydrogen peroxide (H2O2)]
as well as released myeloperoxidase (MPO) acitivity has
been investigated. Exogenous pyruvate signiﬁcantly
increased PMN pyruvate, a-ketoglutarate, asparagine, glu-
tamine, aspartate, glutamate, arginine, citrulline, alanine,
glycine and serine in a dose as well as duration of exposure
dependent manner. Moreover, increases in O2
- formation,
H2O2-generation and MPO acitivity in parallel with intra-
cellular pyruvate changes have also been detected.
Regarding the interesting ﬁndings presented here we
believe, that pyruvate fulﬁls considerably the criteria for a
potent immunonutritional molecule in the regulation of
the PMN dynamic a-keto and amino acid pools. Moreover
it also plays an important role in parallel modulation of
the granulocyte-dependent innate immune regulation.
Although further research is necessary to clarify pyruvate’s
sole therapeutical role in critically ill patients’ immuno-
nutrition, the ﬁrst scientiﬁc successes seem to be very
promising.
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Introduction
Increasing evidence suggests that the ketone pyruvic acid
(the simplest a-keto acid) may have immunonutritional
signiﬁcance in the modulation of PMN host defence
mechanisms and granulocytic immunoregulation because
of its relevant role in cellular energetics and metabolism
(i.e. as an important source of respiratory cellular fuel or
further metabolic precursors). Indeed, in all prokaryotic or
eukaryotic cells its carboxylate anion (known as pyruvate)
is certainly an important chemical compound in biochem-
istry and therefore it is no particular surprise that pyruvate
not only can be produced by different pathways (i.e. via
glycolysis in which one molecule of glucose breaks down
into two molecules of pyruvate or reversible transamina-
tion reactions, etc.), but also unites several key metabolic
processes (Agam and Gutman 1972; Curi et al. 1989, 1988;
Fauth et al. 1993 and 1990; Frei et al. 1975; Fuchs et al.
1994; Homem de Bittencourt et al. 1993; Ing et al. 1997;
Newsholme et al. 1987; Wu et al. 2005 and 2003).
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into acetyl-CoA, releasing NADH and carbon dioxide in a
process called pyruvate decarboxylation (Fauth et al. 1993
and 1990; Fink 2008, 2007a, b, 2004; Willems et al. 1978).
This oxidative conversion into acetyl-CoA, which is the
main input for a series of reactions named after Hans Adolf
Krebs (awarded the 1953 Nobel Prize) is usually catalysed
by the pyruvate dehydrogenase complex as part of aerobic
respiration (Krebs 1940; 1938). Interestingly, the pyruvate
decarboxylation process occurs inside the mitochondria
after transport of the substrate, pyruvate from the cytosol
(Aires et al. 2008; Brivet et al. 2003; Halestrap 1978;
Vaartjes et al. 1979). Pyruvate decarboxylation is therefore
an important link between the metabolic pathways of
glycolysis, intracellular and mitochondrial amino acid
turnover as well as the Krebs- so-called tri-carboxylic acid
(TCA) cycle (Fink 2008, 2007a, b, 2004; Board and
Newsholme 1996; Board et al. 1990; Brown et al. 2004).
Once in the TCA cycle acetyl-CoA, which conveys the
carbon atoms of pyruvate, can be oxidized to CO2 or serves
as a precursor of numerous amino acids, synthetic meta-
bolic intermediates as well as for macromolecular synthesis
(Chang 1977; Das 2006a, b; Paul et al. 1987; Stjernholm
et al. 1969). As quoted above, another important step in the
formation or use of pyruvate is catalysed by rapid and
reversible transamination reactions, for example catalysed
via alanine transaminase, producing a-ketoglutarate and
alanine (Cicalese et al. 1996a, 1996b; Edlund and Hale-
strap 1988; Gardner and Leese 1988; Selvaraj and Sbarra
1966; Wiemer et al. 1995). For leukocytes this is of major
importance, because a-ketoglutarate, converted from
pyruvate in particular, is responsible for key metabolic and
synthetic roles which are essential in cellular viability (Curi
et al. 1988; Gabbianelli et al. 2007; Mahiout et al. 1997;
Miwa et al. 2000; Ramakrishnan et al. 1998; Zhou and Yu
1998) and can be very rapidly into a precursor of numerous
amino acids, synthetic metabolic intermediates as well as
macromolecular synthesis (Curi et al. 1989, 1988; Fuchs
et al. 1994; Riedel et al. 1992; Serrano and Curi 1989;
Venizelos and Hagenfeldt 1985). Interesting ﬁndings
suggest indeed that a-ketoglutarate, which is also one of
the most important intracellular nitrogen transporters, is not
only a key intermediate in the TCA cycle (coming after
isocitrate and before succinyl CoA) but also can replenish
the cycle in anaplerotic reactions. At this point, it is syn-
thesised by transamination of glutamate or through action
of glutamate dehydrogenase on glutamate (Cheng et al.
2007; Fink 2008, 2004; Frei et al. 1975; Willems et al.
1978).
Another important transamination product formed from
pyruvate is alanine, which is most commonly produced
by reductive amination (Board and Newsholme 1996
and Board et al. 1990; Curi et al. 1989, 1988). Because
transamination reactions are readily reversible and pyru-
vate pervasive, alanine can be easily formed and thus,
again, has close links to metabolic pathways such as gly-
colysis, gluconeogenesis and the TCA cycle (Fauth et al.
1990); Frei et al. 1975). Furthermore, pyruvate—through
pyruvate carboxylase—can also be converted to oxaloac-
etate by an anaplerotic reaction. Interestingly, oxaloacetate
is not only an important intermediate of the TCA cycle,
but also the ﬁrst designated substrate of the gluconeogenic
pathways of all other cycle intermediates, glycerol or
amino acids (Homem de Bittencourt et al. 1993; News-
holme et al. 1987; Stjernholm et al. 1969; Venizelos and
Hagenfeldt 1985). Additionally, when oxygen is absent or
in short supply, pyruvate can also be transformed to lactate
by lactate dehydrogenase (LDH) (Gardner and Leese 1988;
Serrano and Curi 1989; Willems et al. 1978). LDH is an
ubiquitous enzyme and therefore present in a wide variety
of cells, including neutrophils. It also catalyses the con-
comitant interconversion of NADH and NAD
?.
The goals of this study are therefore to document the
effects of pyruvate incubated in whole blood on neutrophil-
free intracellular amino acid and a-keto acid concentrations
(regarding its role in PMN immunonutrition) as well as on
the activities of released myeloperoxidase (MPO) and the
formation of both superoxide anions (O2
-) and hydrogen
peroxide (H2O2) (as markers of neutrophil function, and in
order to show possible parallels with changes in neutrophil
amino acid concentrations).
Materials and methods
The study was approved by the local ethics committee of
the Justus Liebig University, Giessen, Germany. Ten men
between 24 and 41 years (31 ± 6.3) with an average height
of 179.8 cm (range 173–188) and weight of 82.6 kg (range
75–94) were selected. Those men with metabolic disease
(e.g. diabetes, etc.), cardiopulmonary, neurological, aller-
gic diseases or taking drugs were excluded. Whole blood
samples (lithium-heparinate plastic tubes) were withdrawn
between 08:00 and 09:00 (after 10 h of fasting) with con-
sideration of circadian variations.
Pyruvate
1. To document any dose-dependent effects, whole blood
samples were incubated with different pyruvate con-
centrations (0, 50, 100, 200 or 500 lM and 1 mM) for
120 min. The selected pyruvate concentration corre-
sponded to 0-, -, 1-, 2-, 5- and 10-fold the clinically
achieved plasma concentrations (see Mu ¨hling et al.
(2003) and Riedel et al. (1992) for physiological
values).
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1232. To examine whether there would be a critical duration
of exposure needed to produce any signiﬁcant effects,
whole blood samples were incubated with pyruvate
(1 mM) for 10, 60 or 120 min.
Solutions of pyruvate were prepared and diluted in
Hank’s balanced salt solution (HBSS; Sigma, Deisenhofen,
Germany) and the pH in the test solution was conﬁrmed
to be 7.4. One millilitre of whole blood was incubated with
25 ll of test solution (ﬁnal pyruvate concentrations were
as described above) at 37 C using a vibrating water bath.
Corresponding volumes of HBSS were added to the control
tubes. Prior to processing further, all fractions were imme-
diately cooled in an ice water bath at 4 C and 100 lg/ml
phenyl methyl sulfonyl ﬂuoride (PMSF), 10 lg/ml leupep-
tin, 10 lg/ml pepstatin, as well as 10 lg/ml antipain (all
acquired from Sigma, USA) were added to each plastic
heparin tube before the blood samples; these additions
served to inhibit proteases.
Highly selective separation of PMN from whole blood
PMN cell fractionation and PMN cytolysis from whole
blood after incubation with pyruvate were particularly
interesting aspects of this study concerning the further
analysis which followed [precise details of our PMN-
separation technique have been described previously
(Krumholz et al. 1995, 1993;M u ¨hling et al. 2003, 1999).
Only preparation procedures, which prevent further meta-
bolic activity and thereby reﬂect metabolic state at the time
of sampling are appropriate for: (1) allowing intragranulo-
cyte free amino and a-keto acid metabolism or immune
functions to be analysed with a high degree of accuracy and
precision, and (2) detecting small changes in metabolism.
Thus, the goal must be to accomplish the fastest possible
separation that retains complete activity, preserves cellular
viability (without premature destruction of cellular integ-
rity) and achieves a high degree of cell purity (Haslett et al.
1985; Rebecchi et al. 2000; Welters 2002). Moreover, con-
tinuous mechanical and chemical manipulation, changing
temperatures, as well as sucrose containing density gradi-
ents, etc., may induce adverse effects on PMN dueto aPMN
activation such as spontaneous deformation, increased
activities of extracellular released myeloperoxidase, ele-
vated interleukin-8-transcription, increased PMN adhesion
to glass surfaces, reduced chemotaxis or increased expres-
sion of complement receptors (Berger et al. 1984; Dooley
et al. 1982; Welters 2002). Preliminary studies showed that
despite these precautions, an activation of PMN could not
always be avoided. In this study those cell suspensions
identiﬁed, however, were removed from further analysis
and evaluation (i.e. as indicated by a microscopic or
macroscopic PMN aggregation). Our recent results, again,
indicated that it was always necessary to check cell purity
and viability to ensure precise and valid PML analysis.
Moreover,theseandformerinterestingﬁndingswerealsoan
important reason for us to choose for all incubations a whole
blood model (Krumholz et al. 1995, 1993; McCarthy et al.
1990; Welters 2002; Zhao etal. 2003). Another advantage is
here, that many structures of an inﬂammatory matrix will
remain during the incubation, since the immunological
response of PMN mainly depends on the interactions with
other blood or endothelial cells as well as on the cellular and
immunological processes in the inﬂammatory area itself.
Thus, important parameters remain stable during the incu-
bation (i.e. continuous or physiological food and substrate
supply for the PMN, maintained interactions with other
blood cells, plasmatic inﬂammatory parameters, proteins,
proteases or enzymes, etc.). For this reason there is an
important advantage: the following ﬁndings in PMN are the
results of nutrient interaction and biochemical communi-
cationofPMNwithallstructureslocatedinwholebloodand
not only the results of a physiologically, biochemically and
nutritionally environment-deprived single cell type. This
offers a maximum proximity to the clinical question: do
patients with serious diseases have a beneﬁt from pyruvate-
enriched immunonutrition?
For the above reasons, we did not choose a sucrose
containing density gradient (i.e. Ficoll
 ) but Percoll
 -
gradient method for granulocyte separation. Our proce-
dure is a further development of the methods described
by Eggleton et al. (1989) and Krumholz et al. (1995,
1993), which allowed very rapid and highly selective
enrichment of PMLs from very small quantities of blood.
Although we used 4 ml of whole blood, 0.2 ml was
enough for the isolation of sufﬁcient granulocytes for
HPLC analysis. Cooling of the whole blood samples and
of the gradients to 4 C did not have an effect on gran-
ulocyte quality (i.e. as was conﬁrmed by light micros-
copy), and as described above, large numbers of cells
could be separated with a high level of vitality, even
from small quantities of whole blood. Cell yields were
determined at the same time that vitality was measured.
For duplicate determination, the percentage deviation in
the numbers of cells amounted to less than 2%. Sepa-
ration of PMN was accomplished using a cooled (4 C)
Percoll
 -gradient (Pharmacia, Uppsala, Sweden). Three
4 ml portions (R = 12 ml) of cooled whole blood from
each volunteer were overlaid onto previously prepared
and pre-cooled (4 C) 70/55% (in 0.9% NaCl) Percoll
 -
gradients before centrifugation at 3509g for 15 min at
4 C (Biofuge
 , Heraeus, Hanau, Germany). This sepa-
rates the PMN as a small layer between the erythrocyte
and monocyte layers. The PMN was carefully removed
from the sample and suspended in 10 ml cooled (4 C)
phosphate-buffered saline (PBS) stock buffer (diluted
Effects of pyruvate on PMN immunonutrition 1079
1231:10, v/v; 109PBS stock buffer, without Ca
2?/Mg
2?,
Gibco, Karlsruhe, Germany). After a second centrifuga-
tion step (3509g for 5 min at 4 C), the PBS buffer was
discarded and the erythrocytes remaining in the sample
were hypotonically lysed using 2 ml of cooled (4 C)
distilled water (Pharmacia, Uppsala, Sweden). After 20 s
the PMN fraction was immediately brought back to
isotonicity by the addition of 1 ml of 2.7% NaCl
(Merck, Darmstadt, Germany) at 4 C and resuspended by
adding 10 ml of diluted stock PBS buffer. After a third
centrifugation step (3509g for 5 min at 4 C) the PBS
buffer was discarded and the PMN fraction again
resuspended (200 ll PBS buffer). Subsequently, all PMN
fractions were combined and two aliquots of resuspended
sample were removed for microscopy (in this study the
average purity of the separated cells was 97.6 ± 0.8%
and the average viability was 98.4 ± 0.7% because
samples with a PMN purity and vitality B95% were
discarded). On average, the cell fractionation procedure
lasted 35 ± 6 min. Immediately after preparation, the
extracted PMN samples were frozen at -80 C before
lyophilisation (freeze dryer CIT-2
 , Heraeus, Hanau,
Germany). These conditions allowed for a PMN lysis,
which was not chemically mediated and guaranteed
longer analyte stability during extended storage of the
sample. Samples prepared in this manner were stored at
-80 C until analysed within a period not exceeding
4 weeks. The purity, determined in duplicate in the ﬁrst
aliquot by dyeing with ‘‘Tu ¨rk’s Solution
 ’’ (Merck) and
viability, determined in the second aliquot by exclusion
of ‘‘Trypan Blue
 ’’ (Merck) was examined and veriﬁed
by light microscopy (Zeiss, Oberkochen, Germany). Cell
yields were determined at the same time that viability
was measured; samples with a PMN purity and viability
\95% were discarded. In parallel, plasma samples
(100 ll) were separated, lyophilised and stored using
known techniques. Overall, this method allows a very
rapid and selective enrichment of neutrophils while
preserving high cellular viability and integrity from very
small quantities of whole blood.
Chromatographic amino and a-keto acid analysis
Amino and a-keto acids in PMN were quantiﬁed using
previously described methods which fulﬁlled the strict
criteria required for ultrasensitive, comprehensive amino
acid and a-keto acid analysis, specially developed and
precisely validated in our institute for this purpose.
Moreover, the coefﬁcients of variations (for method
reproducibility and reproducibilities of retention times)
were also within normal ranges (for details see Mu ¨hling
et al. 2003, 1999). PMN amino acid concentrations are
given in 10
-16 mol per neutrophil-cell; PMN a-keto acid
concentrations are given in 10
-17 mol per neutrophil-cell.
Preparation of derivatization reagent
For the ﬂuorescence labelling of the a-keto acids, we used
o-phenylenediamine (OPD, Sigma, Deisenhofen, Germany).
Since oxidation of OPD inﬂuences the results in a negative
way (the oxidised reagent causes variation in the ﬂuores-
cence intensity) the brown powder must be re-crystallised
prior to use. Although the amount of reactive OPD is
less when using the oxidised form of the reagent, this re-
crystallisation procedure is necessary even when starting
with the originally supplied substance. The o-phenylenedi-
amine was dissolved in heptane at a temperature of
100–120 C (oil bath, Merck) and the heptane subsequently
evaporated in a rotary evaporator (Merck). This procedure
yielded a white powder after drying. With storage under N2
(Sigma, Deisenhofen, Germany) and at 4 C in a dark bottle,
the dry substance is useable for several months. For each
batchofanalyses,theOPDreagentmustbefreshlyprepared.
Foreachsample,5 mgofOPDwasdissolvedin5 mlof3 M
HCl (r) and 10 ll of 2-mercaptoethanol (r) was added
to yield OPD-HCl-ME. This reagent solution was stable for
several hours without loss in sensitivity (Fuchs et al. 1994).
Standard samples and precolumn derivatization
procedure
Analytically pure a-keto acids (r) were dissolved in dis-
tilled H2O (Merck) containing 4% human serum albumin
(Merck), immediately lyophilised and stored at -80 C.
The lyophilisates (PMN, plasma and standard samples)
were solubilised in 250 ll of pure methanol (Mallinckrodt
Baker B.V., Deventer, Holland). The methanol also con-
tained the a-keto acid, a-ketovalerate (KV; r) as an HPLC
internal standard. KV is a non-physiological a-keto acid.
After a 3-min incubation and a 3-min centrifugation step
(30009g, Rotixa/KS
 , Tuttlingen, Germany), 200 llo ft h e
extracts was dried under N2 (10 min, 20 C, Messer,
Griesheim, Germany). The OPD-HCl-ME reagent (5 ml)
was then added, and the samples were incubated for 60 min
at 80 C. The derivatization was stopped after exactly
60 min by cooling for 15 min in ice water. Ethyl acetate
(2 ml, r) was added to the samples and mixed for 7 min in
a rotary mixer (Merck) to extract the a-keto acids. After
extraction, the top ethyl acetate layer was then transferred
to a glass vial (2-CRV
 , Chromacoll, Trumbull, USA).
This procedure was repeated twice for each sample. The
combined ethyl acetate portions were dried under N2
(30 min), re-solubilised in 120 ll of methanol and 50 llo f
this mixture was injected onto the HPLC column.
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The ﬂuorescence high-performance liquid chromatography
system (F-HPLC) consisted of a pump with a controller
for gradient programming (600 E
 , Waters, Milford, MA,
USA) and a programmable autosampler (Triathlon
 , Spark,
Netherlands) with a Rheodyne injection valve and a
100 ll sample loop (AS 300
 , Sunchrom, Friedrichsdorf,
Germany). A Nova-Pak
 , 300 9 3.9 mm i.d., RP-C-18,
60A ˚,4lm (Waters) analytical column was used for sepa-
ration. Column temperatures were maintained at 35 C using
a column oven (Knauer, Berlin, Germany). The column
eluent was monitored using a ﬂuorescence spectrophoto-
meter (RF-530
 , Shimadzu, Kyoto, Japan) at an excitation
wavelength of 360 nm and an emission wavelength of
415 nm.Datarecordingandevaluationwasperformedusing
computer integration software (EuroChrom 2000
 , Knauer,
Berlin, Germany). The linear calibration curves were con-
structedbasedonarearatiosofthestandard(St)tothesample
(S)chromatograms([areaketo acid-St/areainternal standard-St] 9
amountorconcentrationofketoacidsinjected =calculation
factor (CF); [areaketo acid-S/areainternal standard-S] 9 CF =
ﬁnal result). The ﬂow rate was maintained at 1.0 ml/min
throughout. For the gradient program and solvents, auto-
matically degassed using a 3-channel degasser (Knauer,
Berlin, Germany) see Mu ¨hling et al. (2003, 1999).
Superoxide anion production
Superoxide anion and hydrogen peroxide production as
well as activity of released myeloperoxidase were deter-
mined photometrically using modiﬁcations of known
methods validated in our institute for this purpose (for
further details see Krumholz et al. 1995, 1993;M u ¨hling
et al. 2007, 2006, 2005, 2004, 2002). Superoxide anion
production was measured by reduction of cytochrome C,
100 mg of cytochrome C (type IV, Sigma, Deisenhofen,
Germany) which was dissolved in 30 mL PBS
 -glucose
buffer. The solution was aliquoted and frozen at -20 C.
Opsonized zymosan (Sigma, Deisenhofen, Germany) was
used to stimulate PMN. It was produced by incubating
100 mg zymosan with 6 mL pool serum for 30 min
at 37 C. After washing with saline and centrifugation
at 3509g (10 min) opsonized zymosan was re-suspended
in 10 mL PBS
 -glucose buffer, aliquoted and frozen at
-20 C. After incubation of whole blood with pyruvate at
37 C, PMN was isolated as described above. Afterwards,
the PMN was then isolated using a modiﬁcation of our
PMN-separation technique (as mentioned above). After
stepwise (15 min and 5 min) centrifugation procedures
(3509g,2 0  C) as well as careful lysis of a few erythrocytes
contaminating the pellet, the pelleted PMN cells were
re-suspended by adding diluted PBS
  (Gibco, Karlsruhe,
Germany) stock buffer. After 7 mL PBS
  stock buffer had
been administered, the tube was centrifuged at 3509g for
5 min (20 C). The supernatant was decanted. Samples with
aPMN purity\96%andthosewith morethan 4%dead cells
were discarded. The PMN concentration required in each
case was adjusted by adding PBS containing 9.99 g glucose
(Merck, Darmstadt, Germany). After PMN isolation,
500 lL zymosan, 150 lL pool serum, 250 lL cytochrome
C and 500 lL isolated PMN suspension (0.8 9 10
6/mL)
and again pyruvate to be tested, were poured into a test tube.
A preparation containing 500 lL buffer instead of zymosan
was used as a zero adjustment. After further incubation for
15 min at 37 C the reaction was stopped by putting the test
tube into ice water. After centrifugation (3509g; 5 min,
4 C) extinction of the supernatant was measured photo-
metrically (546 nm; Digital photometer 6114S
 ; Eppen-
dorf, Germany). The amount of superoxide anion produced
was calculated and resulted from the extinction coefﬁcient
of cytochrome C according to the Lambert–Beer law. All
control probes obtained for standard curves have been pre-
pared, incubated and measured identically.
Hydrogen peroxide production
Hydrogen peroxide production was also determined
photometrically. The method based on horseradish perox-
idase catalysed by oxidation of phenol red by hydrogen
peroxide. Phenol red (Sigma, Deisenhofen, Germany) and
horseradish peroxidase (type II, Sigma, Deisenhofen,
Germany) were added to PMN, which had been stimulated
by opsonized zymosan. Phenol red was dissolved in dou-
ble-distilled water (10 g/L). Horseradish peroxidase was
dissolved in PBS
 -glucose buffer (5 g/L). After incubation
of whole blood with pyruvate at 37 C, PMN was isolated
as described above. Isolated PMN was stimulated by
opsonized zymosan (Sigma, Deisenhofen, Germany). The
ﬁnal test preparation consisted of 500 lL zymosan, 125 lL
pool serum, 12.5 lL horseradish peroxidase, 12.5 lL
phenol red, 12.5 lL sodium azide (200 mmol/L/l; Merck,
Darmstadt, Germany), 500 lL PMN suspension (2 9 10
6
PMN-cells/mL) and again pyruvate. After incubation for
15 min (37 C), the test preparation was centrifuged for
5 min (3509g;4  C). Subsequent to adding 25 lL sodium
hydroxide solution (1.0 normal, Merck, Darmstadt, Ger-
many) the extinction was measured photometrically at
623 nm. All control probes obtained for standard curves
were prepared, incubated and measured identically.
Activity of released myeloperoxidase
Activity of released myeloperoxidase was also determined
photometrically. 1 mmol/L 2.20-azino-di-(3-ethylbenz-
thiazoline) sulphonic acid (ABTS, Sigma, Deisenhofen,
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123Germany) was dissolved in 0.1 mol/L citrate buffer
(Behring, Marburg, Germany; pH 7.4). After incubation of
whole blood with pyruvate at 37 C, 100 lL isolated PMN
suspension (2 9 10
6/mL) was incubated with 0.5 lg
cytochalasin B (Sigma, Deisenhofen, Germany) and again
with pyruvate (5 min; 37 C). After adding 100 lL opso-
nized zymosan and supplementing in order to keep the
concentration constant, the preparation was incubated
again for 10 min (37 C). Then 1 mL ATBS solution was
added. After centrifuging (7009g, 5 min, 20 C) 1 mL of
supernatant was removed and mixed with 1 lL hydroxide
peroxide solution (30%; Merck, Darmstadt, Germany) and
extinction was measured photometrically (405 nm).
Statistical analysis
Statistical analysis and interpretation of the results were
performed in close cooperation with colleagues from the
Department of Medical Statistics, Justus Liebig University,
Giessen, Germany. All tests were performed in duplicate.
Thus our PMN amino acid results represent the mean of
two estimations. After the results were demonstrated to be
normally distributed (Pearson-Stephens test), statistical
methods were performed including Bartlett’s test to check
homogeneity of variance (p B 0.1). If the requirements
were met, ANOVA analysis was conducted. If the
requirements were not fulﬁlled, the Friedmann test was
performed. Probability levels of p B 0.05 versus control
were considered as signiﬁcant. The data are given as
arithmetic means ± standard deviations (mean ± SD).
Results
The free intracellular amino and a-keto acid concentrations,
superoxide anion formation, hydrogen peroxide generation
as well as activity of released myeloperoxidase obtained in
the control cells were within normal physiological ranges
(see Mu ¨hling et al. 2003, 1999) (Table 1). Intracellular
pyruvate levels amounted on average to 6.36 9 10
-17 mol
perneutrophil(PMN) cell(&158 lmol/LPMN cellvolume
[NCV]; plasma: 117.6 ± 42 lmol/L). The intracellular
a-ketoglutarate content at almost 1.28 9 10
-17 mol per
PMN cell (& 32 lmol/L NCV; plasma: 7.6 ± 2.1 lmol/L)
was approximately 3.7 times lower. The intragranulocytic
amino acids glutamine, glutamate and alanine associated
with pyruvate metabolism could also be exactly quantiﬁed:
their average concentrations at 3.11 9 10
-16 mol per PMN
cell (glutamine) [&773 lmol/L NCV; plasma: 546 ±
191 lmol/L], 5.91 9 10
-16 mol per PMN cell (glutamate)
[&1.470 lmol/L NCV; plasma: 31 ± 7 lmol/L]) and
1.94 9 10
-16 mol per PMN cell (alanine) [&482 lmol/L
NCV; plasma: 354 ± 83 lmol/L], respectively, were on
average more than an order of magnitude higher. Further
interesting ﬁndings were also obtained for asparagine,
aspartate, arginine, ornithine, serine and glycine. Their
intracellular contents were on average 0.39 9 10
-16 mol
(asparagine) [&97 lmol/L NCV; plasma: 61 ± 19 lmol/
L], 2.65 9 10
-16 mol (aspartate) [&659 lmol/L NCV;
plasma: 13 ± 4 lmol/L]), 0.35 9 10
-16 mol (arginine)
Table 1 Effects of pyruvate (PYR; 1 mM) incubated with whole
blood for 10, 60 and 120 min on important free intracellular amino
acids (10
-16 Mol per PMN-cell; mean ± SD; n = 10), a-ketoglu-
tarate and pyruvate concentrations in PMN (10
-17 Mol per PMN-cell;
mean ± SD; n = 10)as well as on PMN superoxide anion production
[O2
-; fmol/(PMN min)
-1], hydrogen peroxide formation [H2O2;
fmol/(PMN min)
-1] and myeloperoxidase activity [MPO; units/l
supernatant]; (mean ± SD; n = 10)
10 min 60 min 120 min
Mean SD Mean SD Mean SD
Control
Asparagine 0.39 0.10 0.41 0.09 0.37 0.09
Glutamine 3.11 0.77 3.32 0.91 2.90 0.86
Aspartate 2.65 0.73 2.80 0.61 2.56 0.57
Glutamate 5.91 1.16 6.28 1.81 5.79 1.56
Ornithine 0.46 0.08 0.49 0.08 0.45 0.09
Arginine 0.35 0.07 0.37 0.07 0.34 0.08
Citrulline 0.14 0.03 0.14 0.03 0.14 0.03
Serine 2.30 0.44 2.22 0.53 2.07 0.45
Glycine 2.47 0.56 2.35 0.49 2.29 0.58
Alanine 1.94 0.46 1.86 0.46 1.81 0.59
a-Ketoglutarate 1.28 0.30 1.25 0.34 1.17 0.35
PYRUVATE 6.36 1.84 6.14 1.93 5.92 1.56
O2
- 3.608 0.959 3.484 0.886 3.264 0.773
H2O2 1.279 0.316 1.263 0.365 1.198 0.304
MPO 0.584 0.157 0.545 0.190 0.499 0.172
PYR (1 mM)
Asparagine 0.40 0.11 0.53*
# 0.12 0.65*
# 0.17
Glutamine 2.92 0.78 4.62*
# 1.27 5.54*
# 1.79
Aspartate 2.87 0.80 4.27*
# 1.32 5.18*
# 1.84
Glutamate 6.90 1.45 11.66*
# 3.91 13.84*
# 4.32
Ornithine 0.48 0.11 0.58 0.14 0.73*
# 0.24
Arginine 0.36 0.10 0.42 0.11 0.48*
# 0.12
Citrulline 0.13 0.03 0.14 0.04 0.16 0.05
Serine 2.19 0.46 2.52 0.67 3.01*
# 0.66
Glycine 2.22 0.44 2.54 0.59 3.41*
# 0.91
Alanine 2.26 0.57 3.34*
# 0.98 5.05*
# 1.82
a-ketoglutarate 1.34 0.37 2.01*
# 0.57 2.78*
# 0.93
PYRUVATE 7.23 2.29 12.07*
# 3.36 19.31*
# 7.54
O2
- 4.652 1.195 10.306*
# 3.051 17.091*
# 6.560
H2O2 1.565 0.437 3.182*
# 0.846 4.992*
# 1.926
MPO 0.672 0.211 1.208*
# 0.413 1.502*
# 0.738
* p B 0.05 versus control values; # p B 0.05 versus 10 min
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123[&87 lmol/L NCV; plasma: 79 ± 20 lmol/L], 0.46 9
10
-16 mol (ornithine) [&114 lmol/L NCV; plasma:
42 ± 20 lmol/L],2.30 9 10
-16mol(serine)[&572 lmol/L
NCV; plasma: 118 ± 33 lmol/L], 2.47 9 10
-16 mol
(glycine)[&614 lmol/LNCV;plasma:251 ± 53 lmol/L])
and 0.14 9 10
-16 mol (citrulline) [&34.8 lmol/L NCV;
plasma: 32 ± 9 lmol/L]) per PMN cell, respectively.
However, the composition of these free amino acid and
a-keto acid pools does not appear to be arbitrary in any way.
When comparing the intra versus the extracellular concen-
tration gradient (i:e), the results painted a very different
picture: for pyruvate (i:e: 1.3), glutamine (i:e: 1.4), alanine
(i:e: 1.3), arginine (i:e: 1.1), serine (i:e: 4.8) and glycine (i:e:
2.4) not only high plasma but also high intracellular con-
centrationshavebeenfound,whilea-ketoglutarate(i:e:4.2),
glutamate (i:e: 47.4), aspartate (i:e: 50.6), asparagine (i:e:
1.6), ornithine (i:e: 2.7) with low plasma concentrations
apparently accumulated within the neutrophils.
Effects of pyruvate on free a-keto acid pool in PMN
1 mM pyruvate signiﬁcantly increased pyruvate and
a-ketoglutarate proﬁles in a duration of exposure depen-
dent manner (PMN incubation for C60 min, Table 1).
Following low pyruvate doses (50 lM, PMN incubation
for 120 min), concentrations of free intracellular a-keto
acids remained unaffected. In the presence of higher
pyruvate concentrations (PMN incubation for 120 min)
signiﬁcant dose-dependent increases in PMN pyruvate and
a-ketoglutarate (C100 lM) were observed (Fig. 1). PMN
free a-ketobutyrate, a-ketoisovalerate, a-ketoisocapronate,
p-hydroxy-phenylpyruvate and a-keto-b-methyl-valerate
proﬁles remained unaffected.
Effects of pyruvate on free amino acid pool in PMN
Concentrations of free intracellular amino acids were
unaffected by 50 lM pyruvate (PMN incubation for
120 min), respectively. Following higher pyruvate con-
centrations (PMN incubation for 120 min), signiﬁcant
dose-dependent increases in PMN glutamate, asparagine,
glutamine, aspartate, alanine (C100 lM, Fig. 2), ornithine
and arginine (C500 lM, Fig. 3), as well as in serine and
glycine (C1 mM, Fig. 4) were observed. Moreover, 1 mM
pyruvate (PMN incubation for C60 min) signiﬁcantly
increased PMN glutamate, glutamine, asparagine, aspar-
tate, alanine, ornithine, arginine, glycine and serine in
duration of exposure-dependent manner (Table 1). PMN-
free citrulline, lysine, leucine, valine, methionine, taurine,
hypotaurine, threonine, a-aminobutyrate, tyrosine, trypto-
phane, phenylalanine and histidine proﬁles remained
unaffected.
Effects of pyruvate on oxidative response
and myeloperoxidase activity
All PMN immune functions tested were unaffected up
to 50 lM pyruvate. In the presence of higher pyruvate
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Fig. 1 Free intracellular pyruvate (PYR) and a-ketoglutarate (KG)
concentrations in PMN-cells following pyruvate incubation (0, 50,
100, 200, 500 lM and 1 mM; 120 min) of whole blood in vitro. PMN
amino acid concentrations are given in 10
-17 Mol per PMN-cell
(mean ± SD; n = 10). *p B 0.05 versus control values
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Pyruvate - incubation [ µM ]
Fig. 2 Free intracellular glutamine (gln), glutamate (glu), asparagine
(asn), aspartate (asp), and alanine (ala) concentrations in PMN-cells
following pyruvate incubation (0, 50, 100, 200, 500 lM and 1 mM;
120 min) of whole blood in vitro. PMN amino acid concentrations are
given in 10
-16 Mol per PMN-cell (mean ± SD; n = 10). *p B 0.05
versus control values
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123supplementation superoxide anion generation (C100 lM),
hydrogen peroxide formation (C100 lM) and MPO activ-
ity (C200 lM) increased signiﬁcantly in a dose-dependent
manner (PMN incubation for 120 min, Fig. 5). Relevant
changes in PMN immune functions tested mainly occurred
with PMN incubation for 60 min or longer (Table 1).
Discussion
For the ﬁrst time the immunonutritional role of pyruvate on
neutrophils (PMN), free a-keto and amino acid proﬁles,
important reactive oxygen species (ROS) produced
[superoxide anion (O2
-), hydrogen peroxide (H2O2)] as
well as released myeloperoxidase (MPO) activity has been
investigated. The results of our study presented here
showed that exogenous pyruvate—incubated in whole
blood—led to a signiﬁcant increase in PMN intracellular
pyruvate content, indicating a relevant transport across the
plasmatic cell membrane. Indeed, essential to the roles of
monocarboxylates such as lactate and pyruvate in cellular
metabolism and metabolic communication between tissues
is their rapid transport through different cell membranes,
which for example is catalysed by a recently identiﬁed
family of proton-linked monocarboxylate transporters
(MCT’s) or simply by diffusion (Brivet et al. 2003;
Burckhardt and Burckhardt 2003; Kielducka et al. 1981;
Kozlova et al. 1983; Lamers and Hulsmann 1975). MCT’s
are located at the plasma but also subcellular membranes
(i.e. mitochondria) of human cells and classically transport
metabolites across plasma membranes, directionally con-
trolled by proton and metabolite concentrations and inde-
pendently of energy input (Hume et al. 1978; Jolkver et al.
2009; Merezhinskaya and Fishbein 2009). Moreover, there
is scientiﬁc evidence for the existence of a facilitated dif-
fusion carrier, which speciﬁcally mediates the translocation
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Fig. 3 Free intracellular ornithine (orn), arginine (arg) and citrulline
(cit) concentrations in PMN-cells following pyruvate incubation (0,
50, 100, 200, 500 lM and 1 mM; 120 min) of whole blood in vitro.
PMN amino acid concentrations are given in 10
-16 Mol per PMN-cell
(mean ± SD; n = 10). *p B 0.05 versus control values
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Pyruvate - incubation [ µM ]
Fig. 4 Free intracellular glycine (gly) and serine (ser) concentrations
in PMN-cells following pyruvate incubation (0, 50, 100, 200, 500 lM
and 1 mM; 120 min) of whole blood in vitro. PMN amino acid
concentrations are given in 10
-16 Mol per PMN-cell (mean ± SD;
n = 10). *p B 0.05 versus control values
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Fig. 5 Effects of different pyruvate concentrations (0, 50, 100, 200,
500 lM and 1 mM; 120 min) incubated with whole blood for
120 min on PMN superoxide anion production [O2
-; fmol/
(PMN min)
-1], hydrogen peroxide formation [H2O2; fmol/
(PMN min)
-1] and myeloperoxidase activity [MPO; units/l superna-
tant]; (mean ± SD; n = 10). *p B 0.05 versus control values
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123of pyruvate. This transport system, which has been found
in the plasma membrane of Trypanosoma brucei (blood-
stream form), differs from other known monocarboxylate
carriers present in the mitochondrial and/or plasma mem-
brane of eukaryotic cells because of its high speciﬁcity for
pyruvate and due to the fact that it does not transport
L-lactate (Edlund and Halestrap 1988; Halestrap 1978;
Poole et al. 1989; Wiemer et al. 1995). Interestingly, some
important drugs may inﬂuence pyruvate transport mecha-
nisms or even cellular pyruvate degradation. For example,
Aires et al. (2008) reported the inhibition of the mito-
chondrial pyruvate uptake by the anticonvulsive drug val-
proic acid. But different antipsychotic drugs with clinically
equivalent doses (i.e. chlorpromazine, thioridazine ﬂu-
phenazine, thiothixene, etc.) are able to inhibit the pyruvate
dehydrogenase complex (PDHC) to varying extents, too
(Bakowski and Parekh 2007; Chen et al. 1998; Zhang et al.
2009).
Furthermore, although our study does not allow to infer
whether the effects were direct (i.e. following uptake of
important substrates by neutrophils produced from other
blood cells) or metabolically induced changes brought
about by pyruvate incubation of whole blood (i.e. follow-
ing intracellular pyruvate conversion), however, referring
to our ﬁndings we also note an relevant role of pyruvate as
an important intragranulocyte substrate of various a-keto
and amino acid pathways (Agam and Gutman 1972;
Mahiout et al. 1997; Miwa et al. 2000; Newsholme et al.
1987; Selvaraj and Sbarra 1966; Serrano and Curi 1989;
Vaartjes et al. 1979; Willems et al. 1978). Since intracel-
lular pyruvate increases the concentrations of a-ketoglu-
tarate as well as glutamine, glutamate, asparagine,
aspartate, alanine, arginine, ornithine, glycine and serine
were also signiﬁcantly elevated in a dose as well as dura-
tion of exposure dependent manner. A more precise look at
the constitution of PMN amino and a-keto acid changes
favour the hypothesis that increases in neutrophil free
pyruvate concentrations are mainly followed by pyruvate
conversion into important amino and a-keto acid deriva-
tives (Curi et al. 1989, 1988; Fuchs et al. 1994;M u ¨hling
et al. 2010, 2007, 2005, 2002). Indeed, our assumption that
this metabolisation processes also occurs within PMN
cells, may particularly be supported with regard to very
similar immunonutritional ﬁndings induced by a-ketoglu-
tarate, alanyl-glutamine, ornithine or arginine in other
leukocyte cells or even neutrophils. We therefore strongly
suggest that pyruvate may act as preliminary stage sub-
strate for subsequent intracellular metabolization. Inter-
estingly, one of the most important cellular biochemical
processes in which pyruvate is involved is its oxidative
degradation, catalyzed by the pyruvate dehydrogenase
complex (PDH) as part of aerobic respiration. The con-
version—very far from equilibrium—of pyruvate to form
acetyl-CoA-accessorily releasing NADH and CO2 via
decarboxylation is known as an important link reaction
between the metabolic pathways of glycolysis and of
course the citric acid cycle. There are either used as a
substrate for oxidative phosphorylation, therefore serving
as a respiratory fuel source or as a precursor of many
synthetic intermediates and metabolic pathways (i.e. urea
cycle [i.e. in the form of aspartate produced from oxalac-
etate] fatty acid, isoprenoid biosynthesis, etc.) (Agam and
Gutman 1972; Board and Newsholme 1996, 1990; Brown
et al. 2004; Newsholme et al. 1987; Stjernholm et al. 1969;
Witko-Sarsat et al. 2000). Indeed, an absence of this
enzyme complex has serious implications for the affected
patients. For example, malfunction of the citric acid cycle
due to PDH deﬁciency deprives the body of energy and
leads to an abnormal buildup of lactate resulting in lactic
acidosis in newborns and often presents with clinical signs
like severe lethargy, poor feeding, tachypnea or cases of
death (Curi et al. 1989 and 1988; Gardner and Leese 1988;
Paul et al. 1987; Su et al. 2007; Venizelos and Hagenfeldt
1985). But for neutrophils, especially, the reversible
transamination of pyruvate by the alanine aminotransferase
(also known as glutamic pyruvic transaminase, GPT), also
seems to be of further importance concerning their physi-
ological tasks in whole body immune defense. In this case
amino groups are transferred from glutamate to pyruvate
producing alanine and a-ketoglutarate which themselves in
turn can directly be shunted into the tricarboxylic acid
cycle and oxidatively decarboxylated to succinyl-CoA by
the a-ketoglutarate dehydrogenase complex (Fink 2004;
Frei et al. 1975; Taylor et al. 2005; Willems et al. 1978).
Furthermore, pyruvate may also be catalysed by an irre-
versible anaplerotic carboxylation (metabolized by pyru-
vate carboxylase), which provides oxalacetate precursors
for the citric acid cycle but also—after conversion into
phosphonenolpyruvate—for gluconeogenesis. Evidence for
this exists as key enzymes for gluconeogenesis such as
fructose-1,6-bisphosphatase had also been found in leuko-
cytes (Agam and Gutman 1972; Fauth et al. 1993, 1990;
Fink 2008 and 2004; Frei et al. 1975; Mackenzie and Lever
2007; Stjernhome et al. 1969). Moreover, pyruvate may
also be a starting point for the ‘‘de novo synthesis’’ of
alanine, serine and glycine as well as glucose. Enzymes
required for this, especially NADPH-forming metabolic
pathways, are certainly present in PMN cells as others have
shown (Agam and Gutman 1972; Curi et al. 1989 and
1988; Fink 2008; Frei et al. 1975; Fuchs et al. 1994; Engel
et al. 2009a, b;M u ¨hling et al. 2010 and 2005; Newsholme
et al. 1987; Serrano and Curi 1989). Concerning to the
present but also former ﬁndings we therefore strongly
believe, that the indirect availability of pyruvate in the
form of glutamate, glutamine, a-ketoglutarate, alanine,
asparagine, aspartate, arginine, ornithine, serine or glycine
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123may emphasise the fundamental importance of this mole-
cule in restoring pathophysiological depleted amino and
a-keto acid pools (Mu ¨hling et al. 2001). Thus indirect
regulation of arginine, ornithine or aspartate (i.e. via
oxalacetate) metabolism (for example used as a substrate
for the enzymes of the urea cycle or formation of phos-
phoserine and serine), the synthesis of •NO required for
PMN activation and ultimately the formation of glutamine,
glutamate or a-ketoglutarate metabolism (i.e. used for
glutathione, proline, purine and pyrimidine synthesis,
export of glutamate in exchange for import of cystine and
following conversion to cysteine, synthesis of glucosa-
mines or NAD?, etc.) can all be modulated by pyruvate-
enriched immunonutrition in PMN (Agam and Gutman
1972; Curi et al. 1989, 1988; Fink 2008; Frei et al. 1975;
Fuchs et al. 1994; Engel et al. 2009a, b;M u ¨hling et al.
2010, 2005; Newsholme et al. 1987; Serrano and Curi
1989; Wu et al. 2005, 2003).
Nevertheless, the conversion of pyruvate does not just
supply important precursors for the above-mentioned
metabolic pathways, since it also provides energy-rich
molecules such as nicotinamide adenine dinucleotide
phosphate (NADPH) or guanosine-50-triphosphate (GTP).
For example NADPH can not only arise from the conver-
sion of pyruvate by pyruvate dehydrogenase, but also from
the catalytic activities of the TCA cycle enzymes isocitrate,
a-ketoglutarate and malate dehydrogenase (Board et al.
1990; Brown et al. 2004; Chang et al. 1977; Mu ¨hling et al.
2010). Moreover, succinyl-CoA synthetase catalyzes
another important step in the TCA cycle which involves the
substrate-level phosphorylation of guanosine-50-diphos-
phate to GTP, which acts as a important source of energy
or as an activator of substrates in metabolic reactions (i.e.
protein synthesis), like that of ATP, but more speciﬁc.
Indeed, Hyslop et al. (1984) found that neutrophil
homogenates contained a high afﬁnity guanosine triphos-
phatase (GTPase) activity during chemotactic peptide
stimulation in neutrophils. Furthermore, Woodman et al.
(1988) described a relevant role for de novo protein syn-
thesis in maintaining or augmentation of the chemotactic
peptide-induced respiratory burst in neutrophils, manufac-
turing O2
-. However, a closer look to granulocytic immune
functions shows, that not only GTPase but also NADPH-
oxidase (NADPH-O) in particular, which can be found in
the plasma membrane as well as in the membrane of
phagosomes, plays a pivotal role in human immune regu-
lation (Kang et al. 2002; Klein et al. 1990; Kobayashi et al.
2001). The complex is normally latent in neutrophils and is
activated to assemble in the membranes during respiratory
burst (Mu ¨hling et al. 2010, 2006, 2005, 2004, 2002). It
primarily generates superoxide, a highly reactive free
radical, by transferring electrons from NADPH inside the
cell across the membrane and coupling these to molecular
oxygen. In phagosomes or outside the cell, superoxide can
spontaneously form hydrogen peroxide that will undergo
further reactions to generate reactive oxygen species (ROS)
(Newsholme et al. 1987; Wu et al. 2005, 2003; Zhou and
Yu 1998). Superoxide is capable of killing bacteria and
fungi by mechanisms that are not yet fully understood. It
also may inactivate critical metabolic enzymes, initiate
lipid peroxidation and liberate redox active iron, which
allows the generation of indiscriminate oxidants such as the
hydroxyl radical. Superoxide probably kills bacteria
directly as the virulence of many pathogens is dramatically
attenuated when their superoxide dismutase (SOD) genes
are deleted (Engel et al. 2009a, b;M u ¨hling et al. 2010,
2006, 2005, 2004, 2002; Wu et al. 2005, 2003). Therefore,
superoxide is one of the main reactive oxygen species in
neutrophils and as such, SOD plays a key antioxidant role.
However, downstream products of superoxide also include
hydrogen peroxide (H2O2) and hypochlorous acid. In
activated neutrophils during the respiratory burst, HOCl is
produced by myeloperoxidase-mediated (MPO) peroxida-
tion of chloride ions from H2O2. Indeed, a number of
authors described that HOCl contributes to the destruction
of bacteria by inhibition of important biochemical path-
ways [i.e. glucose oxidation (Knox et al. 1948)] or reacting
with a wide variety of their biomolecules including
depletion of adenine nucleotides (i.e. ATP hydrolysis),
DNA and RNA (i.e. inhibition of replication) fatty acid
groups (i.e. lipid hydrolysis which affect membrane per-
meability), cholesterol (forming toxic chlorhydrins) as well
as post-translational modiﬁcations to proteins (i.e. protein
unfolding and aggregation) (i.e. Cicalese et al. 1996a,
1996b; Dahlgren and Karlsson 1999; Ing et al. 1997, Huang
et al. 2009; Wu et al. 2005, 2003). But regarding the
‘‘positive’’ or ‘‘desired’’ bacteriocidal nature of chlorine
solutions induced by HOCl one should bear in mind that
the diapedesis of immunonutritionally (i.e. following
pyruvate) improved neutrophils in inﬂammatorily damaged
extravascular matrices may also paradoxically wreak seri-
ous additional granulocyte-mediated injury to all cells or
tissue structures with the potential risks of aggravating the
course of the disease accidentally. Interestingly, recent
ﬁndings showed that pyruvate may also have some anti-
oxidant and anti-inﬂammatory actions as an effective
scavenger of highly reactive oxygen species, for example
produced by neutrophils (Engel et al. 2009a, 2009b; Mate ´s
et al. 2008;M u ¨hling et al. 2010, 2006, 2005, 2004, 2002).
Overall, referring to our results as well as regarding the
beneﬁcial immunonutritional effects found by others, it
seems clear that pyruvate fulﬁlls the criteria for a potent
molecule in the regulation of the dynamic a-keto and
amino acid pools as well as in modulation of PMN
host defense mechanisms and immunoregulation. Unfor-
tunately, any further clariﬁcation of pyruvate’s sole role of
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123in vivo therapeutic immunonutritional properties may be
associated with important galenical problems, mainly due
to its instability in aqueous solutions. For this reason,
current results which investigated ethyl pyruvate (EP), a
simple aliphatic ester derived from pyruvate, seems very
promising (Fink 2004; Zingarelli 2004). EP has shown to
be safe at clinically relevant doses treatment with EP has
been shown to improve survival and/or ameliorating organ
dysfunction in a wide variety of clinical models of criticall
illnesses as well as it has beneﬁcial effects concerning
disturbed cellular function in vitro (Cai et al. 2009; Cheng
et al. 2007; Fink 2007a, b; Genovese et al. 2009; Lee et al.
2008; Tsung et al. 2005, Wang et al. 2009; Yang et al.
2009; Zhang et al. 2009). For example, EP has demon-
strated anti-inﬂammatory actions, improved bacterial
translocation or hyperpermeability due to endotoxinemia
and may also has beneﬁt in models of sepsis and septic
shock by inhibiting tumor necrosis factor-alpha production
and interleukin-6 mRNA expression in several tissues, or
through a reduction of the enzyme activities of cyclo-
oxygenase-2 or inducible nitric oxide synthase (Dave et al.
2009; Deng et al. 2009; Di et al. 2009; Hollenbach et al.
2008; Liang et al. 2009; Su et al. 2007; Taylor et al. 2005;
van Zoelen et al. 2006). But the beneﬁcial anti-inﬂamma-
tory effects may also be due to modiﬁcations in the
circulating levels of high mobility group box-1 and
NF-kappaB signalling pathways (Fink 2008; Han et al.
2005; Matsumoto et al. 1991; Johansson et al. 2008;S u
et al. 2008; Varma et al. 2006).
Although further research is necessary to clarify pyru-
vate’s sole therapeutical role (for example given as EP) in
critically ill patients immunonutrition, the ﬁrst scientiﬁc
successes seem to be very promising.
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